Table 1.
Demographic data, sertraline dose, and presenting site of sweating for oxybutynin and placebo groups
| Oxybutynin group (n = 66) | Placebo group (n = 74) | Statistics | |
|---|---|---|---|
| Age (years, mean ± SD) | 37.12 ± 11.47 | 38.27 ± 9.47 | t(138) = 0.65, P = 0.52 |
| Height (cm, mean ± SD) | 166.98 ± 10.48 | 165.40 ± 9.71 | t(138) = 0.86, P = 0.39 |
| Weight (kg, mean ± SD) | 71.39 ± 14.07 | 69.60 ± 14.57 | t(138) = 0.80, P = 0.43 |
| Body mass index (mean ± SD) | 25.70 ± 4.61 | 25.63 ± 6.09 | t(138) = 0.06, P = 0.96 |
| Gender (male/female; number; % within same gender) | 27 (50%); 39 (45.3%) | 27 (50%); 47 (54.7%) | χ2 (df = 1; n = 140) = 0.29, P = 0.59 |
| Sertraline dose (mg/day, mean ± SD) | 89.01 ± 49.05 | 77.70 ± 38.50 | t(138) = 1.53, P = 0.13 |
| Duration of sertraline use (days) | 19.66 ± 26.84 | 18.75 ± 25.36 | t(138) = 0.21, P = 0.84 |
| Presenting site of sweating | |||
| Whole body | 37 (60.7%) | 24 (39.3%) | χ2 (df = 4, n = 140) = 8.34, P = 0.08 |
| Head and neck | 12 (33.3%) | 24 (66.7%) | |
| Axilla | 8 (40%) | 12 (60%) | |
| Palms | 2 (33.3%) | 4 (66.7%) | |
Abbreviation: SD, standard deviation.